Prexasertib (LY2606368)|LY 2606368|DC Chemicals
DC Chemicals, Website:www.dcchemicals.com
Product Name: Prexasertib (LY2606368) |CAS: 1234015-52-1|Cat No: DC10796|Other Names: LY 2606368,LY-2606368
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.LY2606368 alone significantly inhibited the cell proliferation in a variety of pancreatic cell lines (SW1990, SU86.86, Bx-PC3, AsPC-1, CFPAC-1, Capan-2, HPAF-II) with SW1990 being the most sensitive (IC50=1.5 nM).
LY2606368 has been reported to inhibit Chk1 auto-phosphorylation activated by DNA damaging agents, and induce phosphorylation of H2AX, a DNA damage maker in multiple cancer cell lines in vitro. In addition, LY2606368 has demonstrated potent single agent activity and potentiates the anti-tumor activity of DNA damaging agents in vivo. Pancreatic cancer is one of the least curable cancers, with an approximate 5% overall 5-year survival for all patients. In SW1990 pancreas orthotopic model, which represents the local and metastatic growth pattern seen in pancreas cancer patients, LY2606368 treatment resulted in over 92% inhibition of primary tumor growth as well as 100% inhibition of metastasis to lymph node, spleen and intestine. The anti-tumor effect of LY2606368 treatment was further demonstrated in comparing with gemcitabine (the standard of care for pancreas cancer patient) in SW1990 orthotopic model. For the detailed information of LY2606368 dihydrochloride, the solubility of LY2606368 dihydrochloride in water, the solubility of LY2606368 dihydrochloride in DMSO, the solubility of LY2606368 dihydrochloride in PBS buffer, the animal experiment (test) of LY2606368 dihydrochloride, the cell expriment (test) of LY2606368 dihydrochloride, the in vivo, in vitro and clinical trial test of LY2606368 dihydrochloride, the EC50, IC50,and affinity,of LY2606368 dihydrochloride, Please contact DC Chemicals.
2018年5月18日星期五
CM-272|CM272|CAS 1846570-31-7
CM-272|CM272|CAS 1846570-31-7
DC Chemicals, Website:www.dcchemicals.com
Product Name: CM-272|CAS: 1846570-31-7|Cat No: DC10795|Other Names: CM-272; CM 272; CM272
CM-272 is a first-in-class reversible dual small molecule inhibitor against G9a and DNMTs in hematological malignancies.
CM-272 is a first-in-class reversible and substrate-competitive dual inhibitor of G9a and DNMTs. In ALL, AML and DLBCL-derived cell lines, CM-272 reduced DNA methylation in the promoter region of specific tumor suppressor genes. CM-272 also inhibited cell proliferation, blocked cell cycle progression and induced apoptosis in a dose-dependent way.
DC Chemicals, Website:www.dcchemicals.com
Product Name: CM-272|CAS: 1846570-31-7|Cat No: DC10795|Other Names: CM-272; CM 272; CM272
CM-272 is a first-in-class reversible dual small molecule inhibitor against G9a and DNMTs in hematological malignancies.
CM-272 is a first-in-class reversible and substrate-competitive dual inhibitor of G9a and DNMTs. In ALL, AML and DLBCL-derived cell lines, CM-272 reduced DNA methylation in the promoter region of specific tumor suppressor genes. CM-272 also inhibited cell proliferation, blocked cell cycle progression and induced apoptosis in a dose-dependent way.
PH-002,PH002|AD treament|apo E4 inhibitor
PH-002,PH002|AD treament|apo E4 inhibitor
DC Chemicals, Website:www.dcchemicals.com
Product Name: PH-002|CAS: 1311174-68-1|Cat No: DC10794|Other Names: PH002,PH-002,PH 002
PH-002 is a small-molecule structure corrector,inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction,a potent candidate drug for the treament of AD(Alzheimer disease)
PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that restores mitochondrial cytochrome c oxidase subunit 1 levels, rescues impairments of mitochondrial motility and neurite outgrowth. PH-002 is an apoE4 structure corrector that reverses the apoE4 detrimental effects. The researchers confirmed that, in human neurons, the misshapen apoE4 protein cannot function properly and is broken down into disease-causing fragments in the cells. This process results in a number of problems commonly found in Alzheimer's disease, including the accumulation of the protein tau and of amyloid peptides.
DC Chemicals, Website:www.dcchemicals.com
Product Name: PH-002|CAS: 1311174-68-1|Cat No: DC10794|Other Names: PH002,PH-002,PH 002
PH-002 is a small-molecule structure corrector,inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction,a potent candidate drug for the treament of AD(Alzheimer disease)
PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that restores mitochondrial cytochrome c oxidase subunit 1 levels, rescues impairments of mitochondrial motility and neurite outgrowth. PH-002 is an apoE4 structure corrector that reverses the apoE4 detrimental effects. The researchers confirmed that, in human neurons, the misshapen apoE4 protein cannot function properly and is broken down into disease-causing fragments in the cells. This process results in a number of problems commonly found in Alzheimer's disease, including the accumulation of the protein tau and of amyloid peptides.
ML 221|ML221|CAS 877636-42-5
ML 221|ML221|CAS 877636-42-5
DC Chemicals, Website:www.dcchemicals.com
Product Name: ML221|CAS: 877636-42-5|Cat No: DC10793|Other Names: ML221; ML 221; ML-221
ML221 is an antagonist of the apelin (APJ) receptor.
Apelin receptor (APJ) antagonist (IC50 values are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively). Displays >37-fold selectivity over the closely related angiotensin II type 1 (AT1) receptor. Exhibits no toxicity towards human hepatocytes at concentrations >50 μM.
DC Chemicals, Website:www.dcchemicals.com
Product Name: ML221|CAS: 877636-42-5|Cat No: DC10793|Other Names: ML221; ML 221; ML-221
ML221 is an antagonist of the apelin (APJ) receptor.
Apelin receptor (APJ) antagonist (IC50 values are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively). Displays >37-fold selectivity over the closely related angiotensin II type 1 (AT1) receptor. Exhibits no toxicity towards human hepatocytes at concentrations >50 μM.
DIM-C-pPhOCH3(C-DIM5)|Nur77 antagonist|CAS 151358-47-3
DIM-C-pPhOCH3(C-DIM5)|Nur77 antagonist|CAS 151358-47-3
DC Chemicals, Website:www.dcchemicals.com
Product Name: DIM-C-pPhOCH3(C-DIM5)|CAS: 33985-68-1|Cat No: DC10792|Other Names:
C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival,
C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival, induction of apoptosis, induced expression of the apoptosis gene/protein TRAIL, and inhibited tumor growth in vivo. C-DIM5 induces G0-G1–phase to S-phase arrest in Panc1 cells, and this is accompanied by Nur77-dependent induction of the cyclin-dependent kinase inhibitor p21.
DC Chemicals, Website:www.dcchemicals.com
Product Name: DIM-C-pPhOCH3(C-DIM5)|CAS: 33985-68-1|Cat No: DC10792|Other Names:
C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival,
C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival, induction of apoptosis, induced expression of the apoptosis gene/protein TRAIL, and inhibited tumor growth in vivo. C-DIM5 induces G0-G1–phase to S-phase arrest in Panc1 cells, and this is accompanied by Nur77-dependent induction of the cyclin-dependent kinase inhibitor p21.
DIM-C-pPhOH(CDIM8)|Nur77 antagonist|CAS 151358-47-3
DIM-C-pPhOH(CDIM8)|Nur77 antagonist|CAS 151358-47-3
DC Chemicals, Website:www.dcchemicals.com
Product Name: DIM-C-pPhOH(CDIM8)|CAS: 151358-47-3|Cat No: DC10791|Other Names:
DIM-C-pPhOH is a Nur77 Antagonist. DIM-C-pPhOH inhibits lung cancer cell and tumor growth in a metastasis model.
Nur77 (NR4A1) antagonist. Inhibits TGF-β induced cell migration of breast cancer cell lines. Promotes ROS/endoplasmic reticulum stress and proapoptotic pathways in pancreatic cancer cell lines. Mimics effects of Nur77 RNAi silencing.
DC Chemicals, Website:www.dcchemicals.com
Product Name: DIM-C-pPhOH(CDIM8)|CAS: 151358-47-3|Cat No: DC10791|Other Names:
DIM-C-pPhOH is a Nur77 Antagonist. DIM-C-pPhOH inhibits lung cancer cell and tumor growth in a metastasis model.
Nur77 (NR4A1) antagonist. Inhibits TGF-β induced cell migration of breast cancer cell lines. Promotes ROS/endoplasmic reticulum stress and proapoptotic pathways in pancreatic cancer cell lines. Mimics effects of Nur77 RNAi silencing.
ML-239|ML239|CAS 1378872-36-6
ML-239|ML239|CAS 1378872-36-6
DC Chemicals, Website:www.dcchemicals.com
Product Name: ML-239|CAS: 1378872-36-6|Cat No: DC10790|Other Names: CID-49843203,CID 49843203,CID49843203,ML-239,ML 239,ML239,1378872-36-6
ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).
ML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ∼24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
DC Chemicals, Website:www.dcchemicals.com
Product Name: ML-239|CAS: 1378872-36-6|Cat No: DC10790|Other Names: CID-49843203,CID 49843203,CID49843203,ML-239,ML 239,ML239,1378872-36-6
ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).
ML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ∼24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
订阅：
博文 (Atom)